141 related articles for article (PubMed ID: 25404688)
1. Intratumoural inflammation and endocrine resistance in breast cancer.
Murray JI; West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2015 Feb; 22(1):R51-67. PubMed ID: 25404688
[TBL] [Abstract][Full Text] [Related]
2. Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors.
Nakao M; Fujiwara S; Iwase H
Trends Cancer; 2018 Jun; 4(6):404-407. PubMed ID: 29860984
[TBL] [Abstract][Full Text] [Related]
3. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
4. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
6. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
Roop RP; Ma CX
Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB; Sudhan DR; Arteaga CL
Cancer Cell; 2020 Apr; 37(4):496-513. PubMed ID: 32289273
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Moy B; Goss PE
Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Gou X; Anurag M; Lei JT; Kim BJ; Singh P; Seker S; Fandino D; Han A; Rehman S; Hu J; Korchina V; Doddapaneni H; Dobrolecki LE; Mitsiades N; Lewis MT; Welm AL; Li S; Lee AV; Robinson DR; Foulds CE; Ellis MJ
Cancer Res; 2021 Dec; 81(24):6259-6272. PubMed ID: 34711608
[TBL] [Abstract][Full Text] [Related]
10. ERα-targeted endocrine therapy, resistance and the role of GPER.
Pepermans RA; Prossnitz ER
Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
[TBL] [Abstract][Full Text] [Related]
11. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
14. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
16. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
Ziauddin MF; Hua D; Tang SC
Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
[TBL] [Abstract][Full Text] [Related]
17. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
18. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.
Sarwar N; Kim JS; Jiang J; Peston D; Sinnett HD; Madden P; Gee JM; Nicholson RI; Lykkesfeldt AE; Shousha S; Coombes RC; Ali S
Endocr Relat Cancer; 2006 Sep; 13(3):851-61. PubMed ID: 16954434
[TBL] [Abstract][Full Text] [Related]
20. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]